American Society of Hirudotherapy

Hirudins and fenestrins of the African medicinal leech Asiaticobdella fenestrata

Schulz L, Tolksdorf C, Rauch BH, Kvist S, Müller C (2025) · Parasitology Research

Preclinical / molecular study: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Study record: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.

Study Profile

Model / material
comparative salivary gland transcriptome analysis of African medicinal leech Asiaticobdella fenestrata with recombinant protein expression and functional characterization
Method
Identification of two putative hirudins and two novel RGD-motif platelet aggregation inhibitors ("fenestrins") from A. fenestrata salivary glands
Main result
Two putative hirudins and two novel "fenestrins" (RGD-motif platelet aggregation inhibitors with unique N-terminal location) functionally characterized; demonstrates African leech species as untapped source of bioactive anticoagulant inspiration

Key Findings

  • Two novel hirudin-like factors with unique N-terminal RGD motif
  • Two new platelet aggregation inhibitors named "fenestrins"
  • Distinct from European hirudin/decorsin structural patterns
  • Recombinant expression and functional characterization completed
  • Extends understanding of leech biodiversity beyond H. medicinalis

Limitations

  • Preclinical characterization only - no clinical application yet
  • Limited to A. fenestrata species
  • RGD motif location significance not fully elucidated
  • Functional assays in vitro only
  • No bridge to clinical use established

Clinical Implications

Schulz 2025 expands the leech bioactive compound landscape by characterizing novel hirudins and fenestrins from the African medicinal leech Asiaticobdella fenestrata. For ASH, this preclinical work extends the species and compound diversity beyond European Hirudo medicinalis (the K040187-cleared species), informing future drug development for synthetic recombinant anticoagulants distinct from device-leech practice.

Related studies

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.